替格瑞洛对冠心病患者介入治疗后心血管不良事件的疗效

Therapeutic effect of tiglillo on cardiovascular adverse events in patients with coronary heart disease after interventional therapy

目的探讨替格瑞洛在预防冠心病介入治疗后心血管不良事件中的应用效果。方法选取廊坊爱德堡医院2018年5月至2019年5月收治的100例冠心病介入治疗患者,根据用药不同分为观察组和对照组,每组50例。比较两组患者治疗前后超敏C反应蛋白和凝血指标,术后1年,两组患者心血管不良事件发生率及临床疗效的比较。结果治疗后,两组患者超敏C反应蛋白和凝血指标较治疗前改善,观察组改善优于对照组,差异有统计学意义(P<0.05)。术后1年,观察组患者心血管不良反应发生率14%(7/50)低于对照组42%(21/50),差异有统计学意义(P<0.05)。观察组患者总有效率98.00%(49/50)高于对照组患者的90.00%(45/50),差异无统计学意义。结论冠心病介入治疗后应用替格瑞洛可降低心血管不良事件发生率,改善了凝血功能,降低炎性反应,可以进一步推广应用。

Objective To investigate the effect of tigrel in preventing cardiovascular adverse events after interventional therapy for coronary heart disease. Method 100 patients with coronary heart disease treated by interventional therapy in Langfang Edburgh Hospital from May 2018 to May 2019 were divided into observation group and control group, 50 cases in each group. The incidence of adverse cardiovascular events and the clinical efficacy of the two groups were compared before and after treatment, and 1 year after operation. Result After treatment, the hypersensitive C-reactive protein and coagulation index of the two groups were improved compared with those before treatment, and the improvement of the observation group was better than that of the control group, the difference was statistically significant(P<0.05). One year after operation, the incidence of adverse cardiovascular reactions in the observation group was 14%(7/50) lower than that in the control group 42%(21/50), the difference was statistically significant(P< 0.05). The total effective rate of the observation group was 98.00%(49/50) higher than that of the control group 90.00%(45/50). There was no significant difference between the two groups. Conclusion Tigrillo can reduce the incidence of adverse cardiovascular events, improve coagulation function and reduce inflammatory reaction after interventional therapy of coronary heart disease, which can be further popularized and applied.